The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Hypoxia-targeted drug delivery
Open accessAbstract
Hypoxia is a state of low oxygen tension found in numerous solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Network biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Schafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
(1989) · PubMed · Cited by 3,343
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Anticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 2,550
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Ward, J. F. (1988) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60611-x · Cited by 1,492
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Rankin, E. B., & Giaccia, A. J. (2016) · Science · doi:10.1126/science.aaf4405 · Cited by 1,340
The Chemistry of the quinonoid compounds
Patai, S. (1974) · UMI Books on Demand · Cited by 1,320
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Complete Structure of the 11-Subunit Bovine Mitochondrial Cytochrome bc 1 Complex
Iwata, S., Lee, J. W., Okada, K., Lee, J. K., Iwata, M., Rasmussen, B., Link, T. A., Ramaswamy, S., & Jap, B. K. (1998) · Science · doi:10.1126/science.281.5373.64 · Cited by 1,253
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Electron transfer by domain movement in cytochrome bc1
Zhang, Z., Huang, L., Shulmeister, V. M., Chi, Y.-I., Kim, K. K., Hung, L.-W., Crofts, A. R., Berry, E. A., & Kim, S.-H. (1998) · Nature · doi:10.1038/33612 · Cited by 1,059
Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.1.2 · Cited by 1,057
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Vaupel, P. W., Schlenger, K., Knoop, C., & Höckel, M. (1991) · PubMed · Cited by 952
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response
Vaupel, P., & Harrison, L. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-4 · Cited by 761
Pegg, A. E. (1990) · PubMed · Cited by 730
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
Galanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Trondl, R., Heffeter, P., Kowol, C. R., Jakupec, M. A., Berger, W., & Keppler, B. K. (2014) · Chem. Sci. · doi:10.1039/c3sc53243g · Cited by 675
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
Chiche, J., Brahimi‐Horn, M. C., & Pouysségur, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00994.x · Cited by 667
Cancer genomics: from discovery science to personalized medicine
Chin, L., Andersen, J. N., & Futreal, P. A. (2011) · Nature Medicine · doi:10.1038/nm.2323 · Cited by 644
Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy
Ang, W. H., & Dyson, P. J. (2006) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200600723 · Cited by 635
Platinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
Overgaard, J., Sand Hansen, H., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., Lindeløv, B., & Jørgensen, K. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(97)00220-x · Cited by 573
Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA
Iyer, V. N., & Szybalski, W. (1964) · Science · doi:10.1126/science.145.3627.55 · Cited by 570
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
A Mitochondria‐Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia
Lv, W., Zhang, Z., Zhang, K. Y., Yang, H., Liu, S., Xu, A., Guo, S., Zhao, Q., & Huang, W. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604130 · Cited by 523
Metal-based anticancer chemotherapeutic agents
Muhammad, N., & Guo, Z. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.02.003 · Cited by 515
Gold compounds as therapeutic agents for human diseases
Berners-Price, S. J., & Filipovska, A. (2011) · Metallomics · doi:10.1039/c1mt00062d · Cited by 495
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Dolan, M. E., Moschel, R. C., & Pegg, A. E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5368 · Cited by 460
Stereotactic body radiation therapy: a novel treatment modality
Lo, S. S., Fakiris, A. J., Chang, E. L., Mayr, N. A., Wang, J. Z., Papiez, L., Teh, B. S., McGarry, R. C., Cardenes, H. R., & Timmerman, R. D. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.188 · Cited by 419
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380
Hypoxia-Sensitive Fluorescent Probes for in Vivo Real-Time Fluorescence Imaging of Acute Ischemia
Kiyose, K., Hanaoka, K., Oushiki, D., Nakamura, T., Kajimura, M., Suematsu, M., Nishimatsu, H., Yamane, T., Terai, T., Hirata, Y., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105937q · Cited by 373
Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo
Zheng, X., Wang, X., Mao, H., Wu, W., Liu, B., & Jiang, X. (2015) · Nature Communications · doi:10.1038/ncomms6834 · Cited by 362
Hypoxia Triggers Subcellular Compartmental Redox Signaling in Vascular Smooth Muscle Cells
Waypa, G. B., Marks, J. D., Guzy, R., Mungai, P. T., Schriewer, J., Dokic, D., & Schumacker, P. T. (2010) · Circulation Research · doi:10.1161/circresaha.109.206334 · Cited by 358
Advanced Drug Delivery Systems of Curcumin for Cancer Chemoprevention
Bansal, S. S., Goel, M., Aqil, F., Vadhanam, M. V., & Gupta, R. C. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0006 · Cited by 353
The importance of new companies for drug discovery: origins of a decade of new drugs
Kneller, R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3251 · Cited by 344
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment
Kumar, V., & Gabrilovich, D. I. (2014) · Immunology · doi:10.1111/imm.12380 · Cited by 329
CC‐1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies
Boger, D. L., & Johnson, D. S. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199614381 · Cited by 319
Checkpoint kinase 1 in DNA damage response and cell cycle regulation
Patil, M., Pabla, N., & Dong, Z. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1307-3 · Cited by 317
Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics
Lee, M. H., Sharma, A., Chang, M. J., Lee, J., Son, S., Sessler, J. L., Kang, C., & Kim, J. S. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00557a · Cited by 317
Self-citationSolution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link
Huang, H., Zhu, L., Reid, B. R., Drobny, G. P., & Hopkins, P. B. (1995) · Science · doi:10.1126/science.270.5243.1842 · Cited by 314
Radiation and High-Dose Metronidazole in Supratentorial Glioblastomas
Urtasun, R., Band, P., Chapman, J. D., Feldstein, M. L., Mielke, B., & Fryer, C. (1976) · New England Journal of Medicine · doi:10.1056/nejm197606172942503 · Cited by 306
Mirabelli, C. K., Johnson, R. K., Sung, C. M., Faucette, L. F., Muirhead, K. A., & Crooke, S. T. (1985) · PubMed · Cited by 295
Development of Azo‐Based Fluorescent Probes to Detect Different Levels of Hypoxia
Piao, W., Tsuda, S., Tanaka, Y., Maeda, S., Liu, F., Takahashi, S., Kushida, Y., Komatsu, T., Ueno, T., Terai, T., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201305784 · Cited by 293
Biological Activity of Complex Ions
DWYER, F. P., GYARFAS, E. C., ROGERS, W. P., & KOCH, J. H. (1952) · Nature · doi:10.1038/170190a0 · Cited by 289
Tomasz, M., & Palom, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00088-0 · Cited by 283
Development of an Azo-Based Photosensitizer Activated under Mild Hypoxia for Photodynamic Therapy
Piao, W., Hanaoka, K., Fujisawa, T., Takeuchi, S., Komatsu, T., Ueno, T., Terai, T., Tahara, T., Nagano, T., & Urano, Y. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05019 · Cited by 275
NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues
Belinsky, M., & Jaiswal, A. K. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689804 · Cited by 269
Schlager, J. J., & Powis, G. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450304 · Cited by 262
Preclinical studies identifying carboplatin as a viable cisplatin alternative
Harrap, K. R. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90015-5 · Cited by 259
Song, X., Liu, X., Chi, W., Liu, Y., Wei, L., Wang, X., & Yu, J. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0224-7 · Cited by 258
Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Cairns, R., Khokha, R., & Hill, R. (2003) · Current Molecular Medicine · doi:10.2174/1566524033479447 · Cited by 254
Patterson, A. V., Ferry, D. M., Edmunds, S. J., Gu, Y., Singleton, R. S., Patel, K., Pullen, S. M., Hicks, K. O., Syddall, S. P., Atwell, G. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0478 · Cited by 250
Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
Duan, J.-X., Jiao, H., Kaizerman, J., Stanton, T., Evans, J. W., Lan, L., Lorente, G., Banica, M., Jung, D., Wang, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701028q · Cited by 239
Design of anticancer prodrugs for reductive activation
Chen, Y., & Hu, L. (2009) · Medicinal Research Reviews · doi:10.1002/med.20137 · Cited by 238
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 238
Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., & Lewis, A. D. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.259 · Cited by 232
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Hunter, F. W., Wouters, B. G., & Wilson, W. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.79 · Cited by 228
Bleomycin: Revival of an old drug
Mir, L. M., Tounekti, O., & Orlowski, S. (1996) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(95)02101-9 · Cited by 227
Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—I
Anlezark, G. M., Melton, R. G., Sherwood, R. F., Coles, B., Friedlos, F., & Knox, R. J. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90671-5 · Cited by 214
Overgaard, J., Sand Hansen, H., Andersen, A. P., Hjelm-Hansen, M., Jørgensen, K., Sandberg, E., Berthelsen, A., Hammer, R., & Pedersen, M. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90917-6 · Cited by 214
Lysyl Oxidase Mediates Hypoxic Control of Metastasis
Erler, J. T., & Giaccia, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3197 · Cited by 213
Electron-affinic Sensitization: I. A Structural Basis for Chemical Radiosensitizers in Bacteria
Adams, G. E., & Cooke, M. S. (1969) · International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine · doi:10.1080/09553006914550741 · Cited by 207
Sternberg, C. N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P. H. T. J., Vekemans, K., van Erps, P., Theodore, C., Koriakine, O., Oliver, T., et al. (2005) · Oncology · doi:10.1159/000084201 · Cited by 206
Szakács, G., Hall, M. D., Gottesman, M. M., Boumendjel, A., Kachadourian, R., Day, B. J., Baubichon-Cortay, H., & Di Pietro, A. (2014) · Chemical Reviews · doi:10.1021/cr4006236 · Cited by 203
Hypoxic Sensitizers: Radiobiological Studies at the Cellular Level
Hall, E. J., & Roizin-Towle, L. (1975) · Radiology · doi:10.1148/117.2.453 · Cited by 201
Semenza, G. L. (2013) · Oncogene · doi:10.1038/onc.2012.578 · Cited by 201
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Ware, D. C., Palmer, B. D., Wilson, W. R., & Denny, W. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00065a006 · Cited by 193
HIFs, angiogenesis, and cancer
Yang, Y., Sun, M., Wang, L., & Jiao, B. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24438 · Cited by 191
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals
Hall, M. D., Failes, T. W., Yamamoto, N., & Hambley, T. W. (2007) · Dalton Transactions · doi:10.1039/b707121c · Cited by 188
DT-diaphorase: a target for new anticancer drugs
Danson, S., Ward, T. H., Butler, J., & Ranson, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.01.002 · Cited by 187
Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3237 · Cited by 185
Mohindra, J. K., & Rauth, A. M. (1976) · PubMed · Cited by 182
Martin Brown, J., Yu, N. Y., Brown, D. M., & Lee, W. W. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90460-0 · Cited by 179
AQ4N: a new approach to hypoxia-activated cancer chemotherapy
Patterson, L. H., & McKeown, S. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1564 · Cited by 178
Discovery and development of natural product oridonin-inspired anticancer agents
Ding, Y., Ding, C., Ye, N., Liu, Z., Wold, E. A., Chen, H., Wild, C., Shen, Q., & Zhou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.015 · Cited by 178
Specific Cell Surface Protein Imaging by Extended Self-Assembling Fluorescent Turn-on Nanoprobes
Mizusawa, K., Takaoka, Y., & Hamachi, I. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304239g · Cited by 177
Bioreductive Drugs: from Concept to Clinic
McKeown, S. R., Cowen, R. L., & Williams, K. J. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.006 · Cited by 174
New insights in Au-NHCs complexes as anticancer agents
Porchia, M., Pellei, M., Marinelli, M., Tisato, F., Del Bello, F., & Santini, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.065 · Cited by 173
Selective chemotherapy of noncycling cells in an in vitro tumor model.
Sutherland, R. M. (1974) · PubMed · Cited by 170
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W.-H., Wu, D.-H., Smaill, J. B., Patterson, A. V., & Ding, K. (2014) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10285 · Cited by 170
Jakupec, M. A., Reisner, E., Eichinger, A., Pongratz, M., Arion, V. B., Galanski, M. S., Hartinger, C. G., & Keppler, B. K. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0490742 · Cited by 164
Colucci, M. A., Couch, G. D., & Moody, C. J. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b715270a · Cited by 156
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155
Anticancer metal drugs and immunogenic cell death
Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 150
Effects of hypoxia on tumor metabolism
Kim, J., Gao, P., & Dang, C. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9060-4 · Cited by 149
Self-citationDelivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study
Renfrew, A. K., Bryce, N. S., & Hambley, T. W. (2013) · Chemical Science · doi:10.1039/c3sc51530c · Cited by 149
Liposomal Texaphyrin Theranostics for Metastatic Liver Cancer
Lee, M. H., Kim, E. J., Lee, H., Kim, H. M., Chang, M. J., Park, S. Y., Hong, K. S., Kim, J. S., & Sessler, J. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09713 · Cited by 149
Self-citationZhang, J., Liu, H., Hu, X., Li, J., Liang, L., Zhang, X., & Tan, W. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03336 · Cited by 145
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
Mistry, I. N., Thomas, M., Calder, E. D. D., Conway, S. J., & Hammond, E. M. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.024 · Cited by 145
Parkinson, G. N., Skelly, J. V., & Neidle, S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000159m · Cited by 143
Third row transition metals for the treatment of cancer
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2015) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2014.0185 · Cited by 143
Failes, T. W., Cullinane, C. M., Diakos, C. I., Yamamoto, N., Lyons, J. G., & Hambley, T. W. (2006) · Chemistry - A European Journal · doi:10.1002/chem.200601137 · Cited by 143
New Ruthenium Complexes for the Treatment of Cancer
Keppler, B. K., Henn, M., Juhl, U. M., Berger, M. R., Niebl, R., & Wagner, F. E. (1989) · Progress in clinical biochemistry and medicine · doi:10.1007/978-3-642-74760-1_3 · Cited by 143
Smith, B. D., Haffty, B. G., Wilson, L. D., Smith, G. L., Patel, A. N., & Buchholz, T. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2520 · Cited by 142
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
Verwilst, P., Han, J., Lee, J., Mun, S., Kang, H., & Kim, J. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.023 · Cited by 140
Self-citationEffects of hypoxia on human cancer cell line chemosensitivity
Strese, S., Fryknäs, M., Larsson, R. L., & Gullbo, J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-331 · Cited by 139
Mitomycin C: Chemical and Biological Studies on Alkylation
Schwartz, H. S., Sodergren, J. E., & Philips, F. S. (1963) · Science · doi:10.1126/science.142.3596.1181 · Cited by 134
Daniels, J. S., & Gates, K. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9510774 · Cited by 134
Chung-Faye, G., Palmer, D. H., Anderson, D., Clark, J., Downes, M., Baddeley, J., Hussain, S. A., Murray, P. I., Searle, P. F., Seymour, L. W., et al. (2001) · PubMed · Cited by 133
Guillén, F., Martínez, M. J., Muñoz, C., & Martínez, Á. T. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9834 · Cited by 133
Cobb, L., Connors, T. A., Elson, L. A., Khan, A. H., Mitchley, B. C. V., Ross, W. C. J., & Whisson, M. E. (1969) · Biochemical Pharmacology · doi:10.1016/0006-2952(69)90267-6 · Cited by 133
Hicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. S., Dorie, M. J., Brown, J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1439 · Cited by 132
Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch, C. J. (1993) · PubMed · Cited by 132
High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy
Eriksson, S. E., Prast‐Nielsen, S., Flaberg, E., Székely, L., & Arnér, E. S. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.016 · Cited by 132
Williamson, S. K., Crowley, J. J., Lara, P. N., McCoy, J., Lau, D. H., Tucker, R. W., Mills, G. M., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3771 · Cited by 132
Albertella, M. R., Loadman, P. M., Jones, P. H., Phillips, R. M., Rampling, R., Burnet, N. G., Alcock, C., Anthoney, A., Vjaters, E., Dunk, C. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4020 · Cited by 131
de Groot, F. M. H., Damen, E. W. P., & Scheeren, H. W. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372634 · Cited by 129
Patel, P., Young, J., Mautner, V., Ashdown, D., Bonney, S. L., Pineda, R. G., Collins, S. I., Searle, P. F., Hull, D., Peers, E. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.80 · Cited by 129
Denny, W. A., & Wilson, W. R. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00156a001 · Cited by 128
DiSilvestro, P. A., Ali, S., Craighead, P. S., Lucci, J. A., Lee, Y.-C., Cohn, D. E., Spirtos, N. M., Tewari, K. S., Muller, C., Gajewski, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4265 · Cited by 127
Hypoxia-Selective Agents Derived from Quinoxaline 1,4-Di-N-oxides
Monge, A., Palop, J. A., de Ceráin, A. L., Senador, V., Martinez, F. J., Sáinz, Y., Narro, S., García, E., & de Miguel, C. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00010a023 · Cited by 124
Konopleva, M., Thall, P. F., Yi, C. A., Borthakur, G. M., Coveler, A. L., Bueso‐Ramos, C. E., Benito, J., Konoplev, S. N., Gu, Y., Ravandi, F., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118455 · Cited by 124
Benito, J., Shi, Y., Szymanska, B., Carol, H., Boehm, I., Lu, H., Konoplev, S. N., Fang, W., Zweidler‐McKay, P. A., Campana, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023108 · Cited by 122
Petruzzella, E., Braude, J. P., Aldrich-Wright, J. R., Gandin, V., & Gibson, D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706739 · Cited by 121
Walton, M. I., Smith, P. J., & Workman, P. (1991) · Cancer Communications · doi:10.3727/095535491820873164 · Cited by 119
The Oxygen Effect in Radiation Inactivation of DNA and Enzymes
Quintiliani, M. (1986) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008614550981 · Cited by 119
Lovering, A. L., Hyde, E. I., Searle, P. F., & White, S. A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4653 · Cited by 110
Hay, M. P., Gamage, S. A., Kovacs, M. S., Pruijn, F. B., Anderson, R. F., Patterson, A. V., Wilson, W. R., Brown, J. M., & Denny, W. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020367+ · Cited by 109
Winski, S. L., Hargreaves, R. H. J., Butler, J. A. V., & Ross, D. (1998) · PubMed · Cited by 109
Hicks, K. O., Pruijn, F. B., Sturman, J. R., Denny, W. A., & Wilson, W. R. (2003) · PubMed · Cited by 108
Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo.
Rauth, A. M., Mohindra, J. K., & Tannock, I. F. (1983) · PubMed · Cited by 108
RSU 1069, a nitroimidazole containing an aziridine group
Stratford, I. J., O’Neill, P., SHELDON, P. W., Silver, A. R., Walling, J. M., & ADAMS, G. E. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90566-6 · Cited by 103
Arambula, J. F., McCall, R., Sidoran, K. J., Magda, D. J., Mitchell, N. A., Bielawski, C. W., Lynch, V. M., Sessler, J. L., & Arumugam, K. (2015) · Chemical Science · doi:10.1039/c5sc03519h · Cited by 102
Self-citationHypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor
Kumar, R., Kim, E. J., Han, J., Lee, H., Shin, W. S., Kim, H. M., Bhuniya, S., Kim, J. S., & Hong, K. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.010 · Cited by 102
Self-citationNitrofurans as radiosensitizers of hypoxic mammalian cells.
Chapman, J. D., Reuvers, A. P., Borsa, J., Petkau, A., & McCalla, D. R. (1972) · PubMed · Cited by 99
Cummings, J., Spanswick, V. J., Tomasz, M., & Smyth, J. F. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00073-2 · Cited by 97
A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy
Liu, P., Xu, J., Yan, D., Zhang, P., Zeng, F., Li, B., & Wu, S. (2015) · Chemical Communications · doi:10.1039/c5cc02149a · Cited by 96
Zeng, L., Chen, Y., Huang, H., Wang, J., Zhao, D., Ji, L., & Chao, H. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201502154 · Cited by 95
Physiologic Mechanisms of Therapeutic Resistance: Blood Flow and Hypoxia
Teicher, B. A. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30105-9 · Cited by 94
Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy
Shin, W. S., Han, J., Verwilst, P., Kumar, R., Kim, J., & Kim, J. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00184 · Cited by 94
Self-citationReductive lactonization of strategically methylated quinone propionic acid esters and amides
Carpino, L. A., Triolo, S. A., & Berglund, R. A. (1989) · The Journal of Organic Chemistry · doi:10.1021/jo00275a012 · Cited by 92
Jameson, M. B., Rischin, D., Pegram, M. D., Gutheil, J. C., Patterson, A. V., Denny, W. A., & Wilson, W. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1188-1 · Cited by 92
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Körner, W., Jungwirth, U., Mohr, T. T., Keppler, B. K., & Berger, W. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.018 · Cited by 92
Overgaard, J., Hansen, H. S., Lindeløv, B., et al. (1991) · Radiotherapy and Oncology · doi:10.1016/0167-8140(91)90202-r · Cited by 91
Anderson, H. D., Wagstaff, J. D., Crowther, D., Swindell, R., Lind, M., McGregor, J., Timms, M. S., Brown, D., & Palmer, P. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90338-0 · Cited by 91
Guise, C. P., Wang, A. T., Theil, A., Bridewell, D. J. A., Wilson, W. R., & Patterson, A. V. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.014 · Cited by 87
P450 enzyme expression patterns in the NCI human tumor cell line panel.
Yu, L. J., Matias, J., Scudiero, D. A., Hite, K. M., Monks, A. P., Sausville, E. A., & Waxman, D. J. (2001) · PubMed · Cited by 86
Singleton, R. S., Guise, C. P., Ferry, D. M., Pullen, S. M., Dorie, M. J., Brown, J. M., Patterson, A. V., & Wilson, W. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4023 · Cited by 85
Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., Joshi, N., Sreebhavan, S., Weinreb, I., Goldstein, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1107 · Cited by 82
Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy
Zhou, Y. M., Maiti, M., Sharma, A. K., Won, M., Yu, L., Miao, L. X., Shin, J. W., Podder, A., Bobba, K. N., Han, J., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.036 · Cited by 82
Self-citationPlatinum Anticancer Drugs and Photochemotherapeutic Agents: Recent Advances and Future Developments
Shaili, E. (2014) · Science Progress · doi:10.3184/003685014x13904811808460 · Cited by 81
Ahn, G., Botting, K. J., Patterson, A. V., Ware, D. C., Tercel, M., & Wilson, W. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.007 · Cited by 81
Phillips, R. M., Loadman, P. M., & Cronin, B. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.355 · Cited by 81
Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D. A., Adkins, D., Okuno, S. H., Lorente, G., Kroll, S., Langmuir, V. K., & Chawla, S. P. (2011) · Oncology · doi:10.1159/000327739 · Cited by 81
Eschwège, F., Sancho-Garnier, H., Chassagne, D., Brisgand, D., Guerra, M., Malaise, E. P., Bey, P., Busutti, L., Cionini, L., Nguyen, T. D., et al. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00327-1 · Cited by 81
Recent Developments in Texaphyrin Chemistry and Drug Discovery
Preihs, C., Arambula, J. F., Magda, D. J., Jeong, H., Yoo, D., Cheon, J., Siddik, Z. H., & Sessler, J. L. (2013) · Inorganic Chemistry · doi:10.1021/ic400226g · Cited by 77
Self-citationModels of hypoxia activated prodrugs: Co(iii) complexes of hydroxamic acids
Failes, T. W., & Hambley, T. W. (2006) · Dalton Transactions · doi:10.1039/b512322d · Cited by 76
Robertson, N., Haigh, A., ADAMS, G. E., & Stratford, I. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90134-1 · Cited by 76
Palmer, B. D., Wilson, W. R., Cliffe, S., & Denny, W. A. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00095a018 · Cited by 74
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)
Denny, W. A., & Wilson, W. R. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689806 · Cited by 73
McCall, R., Miles, M. H., Lascuna, P., Burney, B., Patel, Z., Sidoran, K. J., Sittaramane, V. K., Kocerha, J., Grossie, D. A., Sessler, J. L., et al. (2017) · Chemical Science · doi:10.1039/c7sc02153d · Cited by 73
Self-citationTumor‐Targeting of EGFR Inhibitors by Hypoxia‐Mediated Activation
Karnthaler‐Benbakka, C., Groza, D., Kryeziu, K., Pichler, V., Roller, A., Berger, W., Heffeter, P., & Kowol, C. R. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403936 · Cited by 72
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides
Bonnet, M., Hong, C. R., Wong, W. W., Liew, L. P., Shome, A., Wang, J., Gu, Y., Stevenson, R. J., Qi, W., Anderson, R. F., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01678 · Cited by 72
Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is Expected
Freidlin, B., Korn, E. L., George, S. L., & Gray, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8711 · Cited by 71
Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator
Thiabaud, G., McCall, R., He, G., Arambula, J. F., Siddik, Z. H., & Sessler, J. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604236 · Cited by 71
Self-citationLord, R. M., Hebden, A. J., Pask, C. M., Henderson, I., Allison, S. J., Shepherd, S. L., Phillips, R. M., & McGowan, P. C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00455 · Cited by 70
Saunders, M. I., & Dische, S. (1996) · Europe PMC (PubMed Central) · Cited by 69
Helsby, N. A., Wheeler, S. J., Pruijn, F. B., Palmer, B. D., Yang, S., Denny, W. A., & Wilson, W. R. (2003) · Chemical Research in Toxicology · doi:10.1021/tx025662b · Cited by 69
Wilson, W. R., Hicks, K. O., Pullen, S. M., Ferry, D. M., Helsby, N. A., & Patterson, A. V. (2007) · Radiation Research · doi:10.1667/rr0807.1 · Cited by 69
Hicks, K. O., Myint, H., Patterson, A. V., Pruijn, F. B., Siim, B. G., Patel, K., & Wilson, W. R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.049 · Cited by 69
Naylor, M. A., Swann, E., Everett, S. A., Jaffar, M., Nolan, J., Robertson, N., Lockyer, S. D., Patel, K. B., Dennis, M. F., Stratford, M. R. L., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970744w · Cited by 69
Cited by
Revisiting Fluorescent Calixarenes: From Molecular Sensors to Smart Materials
Kumar, R., Sharma, A., Singh, H., Suating, P., Kim, H. S., Sunwoo, K., Shim, I., Gibb, B. C., & Kim, J. S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00605 · Cited by 538
Self-citationMoradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Self-citationTherapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 484
Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01320-5 · Cited by 426
Metadata
- Authors
- Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 48
- Issue
- 3
- Pages
- 771-813
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2906405458
- Cited by
- 542
- References
- 318
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.